the-mesenteric-lymph-duct-cannulated-rat-model-application-to

The Mesenteric Lymph Duct Cannulated Rat Model: Application to the Assessment of Intestinal Lymphatic Drug Transport

The intestinal lymphatic system plays key roles in fluid transport, lipid absorption and immune function. Lymph flows directly from the small intestine ...

Monash University (Parkville Campus)

Org 45697 (MW 600.7&#x3001; clogP 7.92&#x3001; &#x5927;&#x8C46;&#x6CB9;&#x6EB6;&#x89E3;&#x6027; 50 mg/g) &#x548C; Org 46035 (MW 601.6&#xFF0C;&#x5835;&#x585E; P 8.46&#xFF0C;&#x5927;&#x8C46;&#x6CB9;&#x6EB6;&#x89E3;&#x6027; 40 mg/g&#xFF09; &#x662F;&#x4E24;&#x79CD;&#x6C34;&#x4E0D;&#x6EB6; (&lt; 0.1 microg/ml&#xFF09;&#x3001; &#x9AD8;&#x5EA6;&#x4EB2;&#x8102;&#x6027;&#x514D;&#x75AB;&#x8C03;&#x8282;&#x5242;&#x6D3B;&#x6027;&#x548C;&#x9AD8;&#x5EA6;&#x7C7B;&#x4F3C;&#x7684;&#x5316;&#x5B66;&#x7ED3;&#x6784;&#x4E0E;&#x836F;&#x7269;&#x7684;&#x5019;&#x9009;&#x4EBA;&#x3002;&#x540E;&#x5411;&#x6C34;&#x57FA;&#x7532;&#x57FA;&#x7EA4;&#x7EF4;&#x7D20;/&#x8865;&#x95F4; 80 &#x60AC;&#x6D6E;&#x6E05;&#x9192;&#x65E5;&#x95F4;&#x5927;&#x9F20;&#x53E3;&#x670D;&#xFF0C;&#x8FD9;&#x4E24;&#x79CD;&#x5316;&#x5408;&#x7269;&#x7684;&#x751F;&#x7269;&#x5229;&#x7528;&#x5EA6;&#x8F83;&#x4F4E; &#xFF08;&lt; 2%&#x7684;&#x5242;&#x91CF;&#xFF09;&#x3002; &#x7136;&#x800C;&#xFF0C;&#x751F;&#x7269;&#x5229;&#x7528;&#x5EA6;&#x662F;&#x5927;&#x5927;&#x540E;&#x53E3;&#x670D;&#x957F;&#x94FE;&#x7518;&#x6CB9;&#x4E09;&#x916F;&#x8102; &#xFF08;&#x6A44;&#x6984;&#x6CB9;&#xFF09; &#x5236;&#x8BA2;&#x589E;&#x52A0; (&gt; 5 &#x500D;)&#x3002;&#x968F;&#x540E;&#x7684;&#x7814;&#x7A76;&#x63A2;&#x8BA8;&#x4E86;&#x53EF;&#x80FD;&#x89E3;&#x5236;&#x5242;&#xFF0C;&#x5305;&#x62EC;&#x57FA;&#x4E8E;&#x8102;&#x8D28;&#x7684;&#x914D;&#x65B9;&#xFF0C;&#x589E;&#x5F3A;&#x7EC4;&#x7EC7;&#x7ED3;&#x6784;&#x56FE; 45697 &#x548C; Org 46035 &#x53E3;&#x670D;&#x7684;&#x751F;&#x7269;&#x5229;&#x7528;&#x5EA6;&#x548C;&#x7B2C;&#x4E8C;&#xFF0C;&#x63A2;&#x8BA8;&#x80A0;&#x6DCB;&#x5DF4;&#x7684;&#x6F5C;&#x5728;&#x8D21;&#x732E;&#x8FD0;&#x8F93;&#x5230;&#x80A0;&#x9053;&#x5438;&#x6536;&#x3002;&#x5B9E;&#x9A8C;&#x6570;&#x636E;&#x663E;&#x793A;&#x89E3;&#x914D;&#x65B9;&#x53EF;&#x80FD;&#x63D0;&#x4F9B;&#x7684;&#x53E3;&#x670D;&#x751F;&#x7269;&#x5229;&#x7528;&#x5EA6;&#x663E;&#x8457;&#x4E0A;&#x5347; Org 45697 &#x548C; Org 46035 &#x4E0E;&#x8102;&#x8D28;&#x3001; &#x5171;&#x7BA1;&#x540E; 35-50%&#x7684;&#x5438;&#x6536;&#x5242;&#x91CF;&#x53EF;&#x80FD;&#x8FD0;&#x5F80;&#x4F53;&#x5FAA;&#x73AF;&#x901A;&#x8FC7;&#x80A0;&#x6DCB;&#x5DF4;&#x3002;&#x6709;&#x8DA3;&#x7684;&#x662F;&#xFF0C;&#x8F83;&#x5C11;&#x8102;&#x80AA;&#x53EF;&#x6EB6;&#x6027;&#x6A21;&#x62DF;&#x7684;&#x6DCB;&#x5DF4;&#x8FD0;&#x8F93;&#x3001; Org 46035 &#x662F;&#x4F4E;&#x4E8E; Org 45697 &#x6697;&#x793A;&#x8102;&#x8D28;&#x6EB6;&#x89E3;&#x5EA6;&#x8F83;&#x7EC6;&#x5FAE;&#x5DEE;&#x522B;&#x53EF;&#x80FD;&#x5177;&#x6709;&#x91CD;&#x5927;&#x5F71;&#x54CD;&#xFF0C;&#x6DCB;&#x5DF4;&#x8FD0;&#x8F93;&#x7684;&#x7A0B;&#x5EA6;&#x7EA6; 40%&#x3002;

&#x53E3;&#x670D;&#x751F;&#x7269;&#x5229;&#x7528;&#x5EA6;&#x8BC4;&#x4F30;&#x548C;&#x80A0;&#x6DCB;&#x5DF4;&#x548C;&#x8FD0;&#x8F93;&#x7684;&#x7EC4;&#x7EC7;&#x7ED3;&#x6784;&#x56FE; 45697 Org 46035&#xFF0C;&#x7C7B;&#x4F3C;&#x7269;&#x9AD8;&#x5EA6;&#x4EB2;&#x8102;&#x6027;&#x65B0;&#x578B;&#x514D;&#x75AB;&#x8C03;&#x8282;&#x5242;&#x4E24;&#x79CD;&#x3002;

Org 45697 (MW 600.7, clogP 7.92, soybean oil solubility 50 mg/g) and Org 46035 (MW 601.6, clog P 8.46, soybean oil solubility 40 mg/g) are two poorly water soluble (<0.1 microg/ml), highly lipophilic drug candidates with immunomodulator activity and highly analogous chemical structures. After oral administration to conscious ambulatory rats in an aqueous-based methylcellulose/Tween 80 suspension, the bioavailability of both compounds was low (< 2% of administered dose). However, bioavailability was significantly increased (> 5 fold) after oral administration in a long chain triglyceride lipid (olive oil) formulation. Subsequent studies have explored the potential for solubilising formulations, including lipid-based formulations, to enhance the oral bioavailability of Org 45697 and Org 46035 and secondly to explore the potential contribution of intestinal lymphatic transport to intestinal absorption. The experimental data show that solubilising formulations may provide for significant increases in oral bioavailability for Org 45697 and Org 46035 and that after co-administration with lipid, 35-50% of the absorbed dose may be transported to the systemic circulation via the intestinal lymph. Interestingly, the lymphatic transport of the less lipid soluble analogue, Org 46035 was approximately 40% lower than that of Org 45697 suggesting that relatively subtle differences in lipid solubility can have significant impact on the extent of lymphatic transport.

Oral bioavailability assessment and intestinal lymphatic transport of Org 45697 and Org 46035, two highly lipophilic novel immunomodulator analogues.

Org 45697 (MW 600.7, ClogP 7,92, solubilit&#xE9; dans l&#x26;#39;huile de soja 50 mg / g) et Org 46035 (MW 601.6, obstruer P 8,46, solubilit&#xE9; dans l&#x26;#39;huile de soja 40 mg / g) sont deux mal soluble dans l&#x26;#39;eau (&#x26;lt;0,1 microg / ml), tr&#xE8;s candidats-m&#xE9;dicaments lipophiles ayant une activit&#xE9; immunomodulatrice et des structures chimiques tr&#xE8;s analogues. Apr&#xE8;s administration par voie orale &#xE0; des rats conscients ambulatoires dans une solution aqueuse &#xE0; base de m&#xE9;thylcellulose / Tween 80 suspension, la biodisponibilit&#xE9; des deux compos&#xE9;s a &#xE9;t&#xE9; faible (&#x26;lt;2% de la dose administr&#xE9;e). Cependant, la biodisponibilit&#xE9; a &#xE9;t&#xE9; augment&#xE9; de fa&#xE7;on significative (&#x26;gt; 5 fois) apr&#xE8;s administration par voie orale dans un lipide triglyc&#xE9;ride &#xE0; longue cha&#xEE;ne (huile d&#x26;#39;olive) la formulation. Des &#xE9;tudes ult&#xE9;rieures ont explor&#xE9; le potentiel pour des formulations de solubilisation des lipides, y compris des formulations &#xE0; base, pour am&#xE9;liorer la biodisponibilit&#xE9; orale de Org 45697 et 46035 Org et d&#x26;#39;autre part d&#x26;#39;explorer la contribution potentielle du transport lymphatique intestinal &#xE0; l&#x26;#39;absorption intestinale. Les donn&#xE9;es exp&#xE9;rimentales montrent que les formulations solubilisants peuvent pr&#xE9;voir des augmentations significatives de la biodisponibilit&#xE9; orale de Org 45697 et 46035 Org et que, apr&#xE8;s la co-administration avec des lipides, 35-50% de la dose absorb&#xE9;e peut &#xEA;tre transport&#xE9; dans la circulation syst&#xE9;mique par l&#x26;#39;interm&#xE9;diaire de la lymphe intestinale. Fait int&#xE9;ressant, le transport de la lymphe de l&#x26;#39;analogique moins soluble dans les lipides, Org 46035 a &#xE9;t&#xE9; d&#x26;#39;environ 40% inf&#xE9;rieur &#xE0; celui de Org 45697 sugg&#xE9;rant que des diff&#xE9;rences relativement subtiles dans liposolubilit&#xE9; peut avoir un impact significatif sur l&#x26;#39;ampleur de transport de la lymphe.

&#xC9;valuation de la biodisponibilit&#xE9; orale et des Transports lymphatique intestinale de Org 45697 et 46035 Org, deux fortement lipophiles analogues immunomodulateurs nouveaux

Org 45697 (MW 600.7, ClogP 7,92, Soja-&Ouml;l-L&ouml;slichkeit 50 mg/g) und Org 46035 (MW 601,6, verstopfen P 8,46, Soja-&Ouml;l-L&ouml;slichkeit 40 mg/g) sind zwei schlecht Wasser l&ouml;slich (&lt; 0,1 &micro;g/ml), hochgradig lipophilen Medikament Kandidaten mit Immunmodulator Aktivit&auml;t und sehr &auml;hnliche chemische Strukturen. Nach oraler Verabreichung an bewusste ambulante Ratten in einer w&auml;ssrigen basierende Methylzellulose/Tween 80-Aufh&auml;ngung, die Bioverf&uuml;gbarkeit von beider Verbindungen gering war (&lt; 2 % der verabreichten dosis). Allerdings war die bioverf&uuml;gbarkeit deutlich erh&ouml;ht (&gt; 5 fach) nach oraler Gabe in einem langkettigen Triglyzeride Lipid (Oliven&ouml;l) Formulierung. Sp&auml;tere Studien haben untersucht das Potenzial f&uuml;r L&ouml;sungsmittel Rezepturen, einschlie&szlig;lich Lipid-basierte Formulierungen, um die orale Bioverf&uuml;gbarkeit von Org 45697 und Org 46035 zu verbessern und zweitens erkunden der potenzielle Beitrag von intestinalen lymphatischen transport zu intestinale Resorption. Die experimentellen Daten zeigen, dass L&ouml;sungsmittel Formulierungen vorsehen f&uuml;r betr&auml;chtliche Steigerungen der orale Bioverf&uuml;gbarkeit Org 45697 und Org 46035 und, nachdem die gleichzeitige Gabe mit Lipid, 35-50 % der absorbierten Dosis in den K&ouml;rperkreislauf &uuml;ber die intestinale Lymphe transportiert werden d&uuml;rfen. Interessanterweise war die lymphatische Bef&ouml;rderung von den weniger l&ouml;slichen Lipid-Analog, Org 46035 ca. 40 % niedriger als die der Org 45697 darauf hindeutet, dass relativ geringf&uuml;gige Unterschiede in Lipid L&ouml;slichkeit erhebliche Auswirkungen auf das Ausma&szlig; der lymphatischen Transport haben k&ouml;nnen.

Orale Bioverf&uuml;gbarkeit Bewertung und intestinalen lymphatischen Transport von Org 45697 und Org 46035, zwei hoch lipophilen neuartiger Immunmodulator Analoga.

Org 45697 (600.7 MW, clogP 7.92, solubilit&agrave; olio di soia 50 mg/g) e Org 46035 (MW 601.6, intasare P 8,46, solubilit&agrave; olio di soia 40 mg/g) sono due acqua scarsamente solubili (&lt; 0.1 microg/ml), altamente lipofile candidati della droga con attivit&agrave; immunomodulatore e altamente analoghe strutture chimiche. Dopo somministrazione orale a ratti coscienti ambulatoriale in una sospensione acquosa base metilcellulosa/Tween 80, la biodisponibilit&agrave; di entrambi i composti &egrave; stata bassa (&lt; 2% della dose somministrata). Tuttavia, la biodisponibilit&agrave; &egrave; stato significativamente aumentato (&amp;gt; 5 volte) dopo somministrazione orale in una formulazione di lipidi (olio d&#39;oliva) di trigliceridi a lunga catena. Studi successivi hanno esplorato il potenziale per solubilizzare formulazioni, comprese le formulazioni a base lipidica, per migliorare la biodisponibilit&agrave; orale di Org 45697 e Org 46035 e in secondo luogo per esplorare il potenziale contributo del linfatico intestinale trasporto intestinale di assorbimento. I dati sperimentali mostrano che solubilizzante formulazioni possono prevedere aumenti significativi nella biodisponibilit&agrave; orale per Org 45697 e Org 46035 e che dopo la co-somministrazione con lipidi, 35-50% della dose assorbita pu&ograve; essere trasportato per la circolazione sistemica attraverso la linfa intestinale. &Egrave; interessante notare che, il trasporto linfatico dell&#39;analogo meno lipidi solubili, Org 46035 era circa il 40% inferiore a quello di Org 45697 suggerendo che relativamente sottili differenze di liposolubilit&agrave; possono avere un impatto significativo sulla misura del trasporto linfatico.

Valutazione della biodisponibilit&agrave; orale e trasporto linfatico intestinale di Org 45697 e Org 46035, due altamente lipofile immunomodulatore romanzo analoghi.

ORG 45697&#xFF08;MW 600.7&#x3001;clogP 7.92&#x3001;&#x5927;&#x8C46;&#x30AA;&#x30A4;&#x30EB;&#x306E;&#x6EB6;&#x89E3;&#x5EA6;&#x306F;50mg / g&#xFF09;&#x304A;&#x3088;&#x3073;&#x7D44;&#x7E54;46035&#xFF08;MW 601.6&#x3001;P 8.46&#x3092;&#x8A70;&#x307E;&#x3089;&#x305B;&#x3001;&#x30C0;&#x30A4;&#x30BA;&#x6CB9;&#x3078;&#x306E;&#x6EB6;&#x89E3;&#x5EA6;&#x306F;40 mg / g&#xFF09;&#x306F;&#x975E;&#x5E38;&#x306B;&#x3001;&#x4E8C;&#x3064;&#x306E;&#x96E3;&#x6C34;&#x6EB6;&#x6027;&#xFF08;&#x26;lt;0.1&#x306E;microg / ml&#xFF09;&#x3067;&#x3042;&#x308B;&#x514D;&#x75AB;&#x8ABF;&#x7BC0;&#x6D3B;&#x6027;&#x3092;&#x6709;&#x3059;&#x308B;&#x89AA;&#x6CB9;&#x6027;&#x85AC;&#x7269;&#x5019;&#x88DC;&#x3068;&#x975E;&#x5E38;&#x306B;&#x985E;&#x4F3C;&#x306E;&#x5316;&#x5B66;&#x69CB;&#x9020;&#x3002;&#x6C34;&#x6027;&#x30E1;&#x30C1;&#x30EB;&#x30BB;&#x30EB;&#x30ED;&#x30FC;&#x30B9;/ Tween 80&#x3092;&#x61F8;&#x6FC1;&#x6DB2;&#x4E2D;&#x306E;&#x610F;&#x8B58;&#x5916;&#x6765;&#x30E9;&#x30C3;&#x30C8;&#x306B;&#x7D4C;&#x53E3;&#x6295;&#x4E0E;&#x3057;&#x305F;&#x5F8C;&#x3001;&#x4E21;&#x5316;&#x5408;&#x7269;&#x306E;&#x751F;&#x7269;&#x5B66;&#x7684;&#x5229;&#x7528;&#x80FD;&#x306F;&#x3001;&#xFF08;&#x6295;&#x4E0E;&#x91CF;&#x306E;&#x26;lt;2&#xFF05;&#xFF09;&#x4F4E;&#x304B;&#x3063;&#x305F;&#x3002;&#x3057;&#x304B;&#x3057;&#x3001;&#x751F;&#x7269;&#x5B66;&#x7684;&#x5229;&#x7528;&#x80FD;&#x304C;&#x6709;&#x610F;&#x306B;&#x9577;&#x9396;&#x30C8;&#x30EA;&#x30B0;&#x30EA;&#x30BB;&#x30EA;&#x30C9;&#x8102;&#x8CEA;&#xFF08;&#x30AA;&#x30EA;&#x30FC;&#x30D6;&#x30AA;&#x30A4;&#x30EB;&#xFF09;&#x88FD;&#x5264;&#x3067;&#x3001;&#x7D4C;&#x53E3;&#x6295;&#x4E0E;&#x5F8C;&#xFF08;&#x26;gt; 5&#x500D;&#xFF09;&#x306B;&#x5897;&#x52A0;&#x3057;&#x305F;&#x3002;&#x305D;&#x306E;&#x5F8C;&#x306E;&#x7814;&#x7A76;&#x3067;&#x306F;&#x3001;&#x7D44;&#x7E54;45697&#x304A;&#x3088;&#x3073;Org 46035&#x306E;&#x7D4C;&#x53E3;&#x30D0;&#x30A4;&#x30AA;&#x30A2;&#x30D9;&#x30A4;&#x30E9;&#x30D3;&#x30EA;&#x30C6;&#x30A3;&#x3092;&#x9AD8;&#x3081;&#x308B;&#x305F;&#x3081;&#x306B;&#x3001;&#x7B2C;&#x4E8C;&#x8178;&#x7BA1;&#x5438;&#x53CE;&#x306B;&#x8178;&#x30EA;&#x30F3;&#x30D1;&#x8F38;&#x9001;&#x306E;&#x6F5C;&#x5728;&#x7684;&#x306A;&#x8CA2;&#x732E;&#x3092;&#x63A2;&#x308B;&#x305F;&#x3081;&#x306B;&#x3001;&#x8102;&#x8CEA;&#x30D9;&#x30FC;&#x30B9;&#x306E;&#x88FD;&#x5264;&#x3092;&#x542B;&#x3080;&#x53EF;&#x6EB6;&#x5316;&#x88FD;&#x5264;&#x306E;&#x53EF;&#x80FD;&#x6027;&#x3092;&#x6A21;&#x7D22;&#x3057;&#x3066;&#x304D;&#x305F;&#x3002;&#x5B9F;&#x9A13;&#x30C7;&#x30FC;&#x30BF;&#x306F;&#x3001;&#x53EF;&#x6EB6;&#x5316;&#x88FD;&#x5264;&#x306F;&#x7D44;&#x7E54;45697&#x304A;&#x3088;&#x3073;Org 46035&#x304A;&#x3088;&#x3073;&#x8102;&#x8CEA;&#x3068;&#x306E;&#x5171;&#x6295;&#x4E0E;&#x5F8C;&#x3001;&#x5438;&#x53CE;&#x7DDA;&#x91CF;&#x306E;35&#x304B;&#x3089;50&#x30D1;&#x30FC;&#x30BB;&#x30F3;&#x30C8;&#x306F;&#x8178;&#x30EA;&#x30F3;&#x30D1;&#x3092;&#x4ECB;&#x3057;&#x3066;&#x5168;&#x8EAB;&#x5FAA;&#x74B0;&#x3078;&#x8F38;&#x9001;&#x3055;&#x308C;&#x308B;&#x304B;&#x3082;&#x3057;&#x308C;&#x306A;&#x3044;&#x7D4C;&#x53E3;&#x751F;&#x7269;&#x5B66;&#x7684;&#x5229;&#x7528;&#x80FD;&#x306E;&#x6709;&#x610F;&#x306A;&#x5897;&#x52A0;&#x3092;&#x63D0;&#x4F9B;&#x3059;&#x308B;&#x3053;&#x3068;&#x304C;&#x3067;&#x304D;&#x308B;&#x3053;&#x3068;&#x3092;&#x793A;&#x3057;&#x3066;&#x3044;&#x308B;&#x3002;&#x8208;&#x5473;&#x6DF1;&#x3044;&#x3053;&#x3068;&#x306B;&#x3001;&#x7D44;&#x7E54;&#x5C11;&#x306A;&#x3044;&#x8102;&#x6EB6;&#x6027;&#x30A2;&#x30CA;&#x30ED;&#x30B0;&#x3001;46035&#x306E;&#x30EA;&#x30F3;&#x30D1;&#x8F38;&#x9001;&#x306F;&#x8102;&#x6EB6;&#x6027;&#x3067;&#x6BD4;&#x8F03;&#x7684;&#x5FAE;&#x5999;&#x306A;&#x9055;&#x3044;&#x304C;&#x30EA;&#x30F3;&#x30D1;&#x8F38;&#x9001;&#x306E;&#x7A0B;&#x5EA6;&#x306B;&#x5927;&#x304D;&#x306A;&#x5F71;&#x97FF;&#x3092;&#x53CA;&#x307C;&#x3059;&#x53EF;&#x80FD;&#x6027;&#x304C;&#x3042;&#x308A;&#x307E;&#x3059;&#x3053;&#x3068;&#x3092;&#x793A;&#x5506;&#x3057;&#x3066;&#x3044;&#x308B;&#x7D44;&#x7E54;45697&#x306E;&#x305D;&#x308C;&#x3088;&#x308A;&#x3082;&#x7D04;40&#xFF05;&#x4F4E;&#x304B;&#x3063;&#x305F;&#x3002;

&#x7D4C;&#x53E3;&#x30D0;&#x30A4;&#x30AA;&#x30A2;&#x30D9;&#x30A4;&#x30E9;&#x30D3;&#x30EA;&#x30C6;&#x30A3;&#x8A55;&#x4FA1;&#x3068;&#x7D44;&#x7E54;45697&#x304A;&#x3088;&#x3073;Org 46035&#x3001;&#x4E8C;&#x3064;&#x306E;&#x8178;&#x30EA;&#x30F3;&#x30D1;&#x8F38;&#x9001;&#x9AD8;&#x89AA;&#x6CB9;&#x6027;&#x306E;&#x65B0;&#x898F;&#x514D;&#x75AB;&#x8ABF;&#x7BC0;&#x306E;&#x985E;&#x7E01;

Org 45697 (MW 600.7, clogP 7.92, &#xCF69; &#xC624;&#xC77C; &#xC6A9; &#xD574;&#xB3C4; 50mg/g) &#xBC0F; Org 46035 (MW 601.6, &#xBC29;&#xD574;&#xD560; P 8.46, &#xCF69; &#xC624;&#xC77C; &#xC6A9; &#xD574;&#xB3C4; 40 mg/g)&#xB294; &#xB450; &#xC81C;&#xB300;&#xB85C; &#xBB3C; &#xC218;&#xC6A9; &#xC131; (&lt; 0.1 microg/ml), &#xB192;&#xC740; &#xBE14;&#xB808;&#xBBF8;&#xC26C; immunomodulator &#xD65C;&#xB3D9;&#xACFC; &#xB9E4;&#xC6B0; &#xC720;&#xC0AC;&#xD55C; &#xD654;&#xD559; &#xAD6C;&#xC870;&#xC640; &#xD6C4;&#xBCF4; &#xC57D;&#xBB3C;. &#xADF8;&#xB7EC;&#xB098; &#xC218;&#xC131; &#xAE30;&#xBC18; fd&amp;amp;c/&#xD2B8;&#xC708; 80 &#xC815;&#xC9C0;&#xC5D0;&#xC11C; &#xC758;&#xC2DD; &#xBCF4; &#xC950;&#xC5D0; &#xAD6C;&#xAC15; &#xAD00;&#xB9AC; &#xD6C4; &#xB450; &#xD654;&#xD569;&#xBB3C;&#xC758; bioavailability&#xB294; &#xB0AE;&#xC740; (&#xAD00;&#xB9AC; &#xBCF5;&#xC6A9;&#xB7C9;&#xC758; &lt; 2%). bioavailability&#xB294; &#xD06C;&#xAC8C; &#xAE34; &#xCCB4;&#xC778; triglyceride &#xC9C0;&#xC9C8; (&#xC62C;&#xB9AC;&#xBE0C; &#xC624;&#xC77C;) &#xBC30;&#xD569;&#xC5D0; &#xAD6C;&#xAC15; &#xAD00;&#xB9AC; &#xD6C4; (&amp;gt; 5 &#xBC30;) &#xC99D;&#xAC00; &#xD588;&#xB2E4;. &#xD6C4;&#xC18D; &#xC5F0;&#xAD6C; 45697 Org Org 46035&#xC758; &#xAD6C;&#xAC15; bioavailability&#xC744; &#xD5A5;&#xC0C1; &#xC2DC;&#xD0A4;&#xAE30; &#xC704;&#xD574; &#xC9C0;&#xC9C8; &#xAE30;&#xBC18; &#xC81C;&#xD615;&#xC744; &#xD3EC;&#xD568; &#xD55C; solubilising &#xACF5;&#xBC95;&#xC5D0; &#xB300; &#xD55C; &#xC7A0;&#xC7AC;&#xB825;&#xC744; &#xD0D0;&#xD5D8; &#xD558; &#xACE0; &#xB458;&#xC9F8; &#xCC3E;&#xC544;&#xBCF4;&#xAE30; &#xCC3D; &#xC790; &#xB9BC;&#xD504;&#xC758; &#xC7A0;&#xC7AC;&#xC801;&#xC778; &#xAE30;&#xC5EC; &#xC218;&#xC1A1;&#xC5D0; &#xC7A5; &#xD761;&#xC218;. &#xC2E4;&#xD5D8; &#xB370;&#xC774;&#xD130;&#xB294; solubilising &#xACF5;&#xC2DD; &#xC218; &#xC788;&#xC2B5;&#xB2C8;&#xB2E4; &#xC81C;&#xACF5; &#xD45C;&#xC2DC; &#xAD6C;&#xAC15; bioavailability &#xD06C;&#xAC8C; &#xC99D;&#xAC00; &#xB300; &#xD55C; Org 45697 Org 46035 &#xBC0F; &#xADF8;&#xC5D0; &#xB300; &#xD55C; &#xC9C0;&#xC9C8;, &#xD568;&#xAED8; co-administration &#xD6C4; &#xD761;&#xC218; &#xC120; &#xB7C9;&#xC758; 35-50% &#xCC3D; &#xC790; &#xB9BC;&#xD504;&#xB97C; &#xD1B5;&#xD574; &#xC804;&#xC2E0; &#xC21C;&#xD658;&#xC744; &#xC774;&#xC1A1; &#xB420; &#xC218; &#xC788;&#xC2B5;&#xB2C8;&#xB2E4;. &#xC7AC;&#xBBF8; &#xC788;&#xAC8C;, &#xB35C; &#xC9C0;&#xC9C8; &#xC6A9; &#xD574; &#xC544;&#xB0A0;&#xB85C;&#xADF8; &#xB9BC;&#xD504; &#xC804;&#xC1A1; Org 46035 Org 45697 &#xC81C;&#xC548; &#xC9C0;&#xC9C8; &#xC6A9; &#xD574;&#xB3C4; &#xC0C1;&#xB300;&#xC801;&#xC73C;&#xB85C; &#xBBF8;&#xBB18;&#xD55C; &#xCC28;&#xC774; &#xB9BC;&#xD504; &#xC218;&#xC1A1;&#xC758; &#xC815;&#xB3C4;&#xC5D0; &#xC0C1;&#xB2F9;&#xD55C; &#xC601;&#xD5A5;&#xC744; &#xBBF8;&#xCE60; &#xC218;&#xC758; &#xADF8;&#xAC83; &#xBCF4;&#xB2E4; &#xB0AE;&#xC740; &#xC57D; 40% &#xC774;&#xC5C8;&#xB2E4;.

&#xAD6C;&#xAC15; bioavailability &#xD3C9;&#xAC00; &#xBC0F; 45697 Org Org 46035, &#xB450; &#xAC1C;&#xC758; &#xB9E4;&#xC6B0; &#xBE14;&#xB808;&#xBBF8;&#xC26C; &#xC18C;&#xC124; immunomodulator analogues&#xC758; &#xCC3D; &#xC790; &#xB9BC;&#xD504; &#xC804;&#xC1A1;.

Org 45697 (600,7 MW, ClogP 7,92, la solubilidad del aceite de soja 50 mg / g) y Org 46035 (601,6 MW, tapar P 8,46, la solubilidad del aceite de soja 40 mg / g) son dos poco solubles en agua (&#x26;lt;0,1 g / ml), muy candidatos lipof&#xED;licas de drogas con actividad inmunomoduladora y estructuras qu&#xED;micas muy an&#xE1;logas. Despu&#xE9;s de la administraci&#xF3;n oral a ratas conscientes ambulatorios en una base acuosa de metilcelulosa / Tween 80 suspensi&#xF3;n, la biodisponibilidad de ambos compuestos fue baja (&#x26;lt;2% de la dosis administrada). Sin embargo, la biodisponibilidad fue significativamente mayor (&#x26;gt; 5 veces) tras la administraci&#xF3;n oral de un l&#xED;pido de triglic&#xE9;ridos de cadena larga (aceite de oliva) formulaci&#xF3;n. Estudios posteriores han explorado la posibilidad de formulaciones solubilizantes, entre ellos a base de l&#xED;pidos formulaciones, para mejorar la biodisponibilidad oral de Org 45697 y Org 46035 y en segundo lugar para explorar la posible contribuci&#xF3;n del transporte linf&#xE1;tico intestinal para la absorci&#xF3;n intestinal. Los datos experimentales muestran que las formulaciones de solubilizaci&#xF3;n puede prever un aumento significativo en la biodisponibilidad oral de Org 45697 y Org 46035 y que despu&#xE9;s de la co-administraci&#xF3;n con los l&#xED;pidos, 35-50% de la dosis absorbida puede ser transportado a la circulaci&#xF3;n sist&#xE9;mica a trav&#xE9;s de la linfa intestinal. Curiosamente, el transporte linf&#xE1;tico del an&#xE1;logo de l&#xED;pidos menos soluble, Org 46035 fue de aproximadamente 40% menor que la de Org 45697 sugiere que las diferencias relativamente sutiles en solubilidad en l&#xED;pidos pueden tener un impacto significativo sobre el grado de transporte linf&#xE1;tico.

Evaluaci&#xF3;n de la biodisponibilidad oral y de transporte linf&#xE1;tico intestinal de Org 45697 y Org 46035, dos nuevos an&#xE1;logos altamente lipof&#xED;licos inmunomoduladores

The clearance (Cl) and volume of distribution (V(ss)) of a lipophilic, lymphatically transported drug, halofantrine (Hf) have been evaluated after intravenous delivery to the systemic circulation in ex vivo lymph and plasma, and compared with the data obtained after administration of a lipid-based emulsion and a lipid-free cosolvent formulation. Systemic Cl and V(ss) were significantly lower (approximately twofold) after delivery of Hf in lymph or the emulsion when compared with the administration in plasma or the cosolvent formulation. Preadministration of drug-free lymph, immediately before administration of drug in plasma, however, resulted in plasma profiles consistent with that obtained after administration of drug in lymph/emulsion. Where drug and lipid entered the systemic circulation coincidentally, systemic Cl of Hf, therefore, appeared to be relatively unaffected by the route of entry to the systemic circulation (i.e. via the lymph or the blood), but more significantly altered by total plasma lipid levels. Because temporal changes to plasma lipid levels occur as a result of the absorption of formulation or food-derived lipids and the infusion of intravenous lipid emulsions, the current data suggest that a mismatch in plasma lipid levels after intravenous and oral administrations may lead to differences in drug Cl and errors in bioavailability assessment.

Intravenous dosing conditions may affect systemic clearance for highly lipophilic drugs: implications for lymphatic transport and absolute bioavailability studies.

To establish a lymph-cannulated mouse model, and use the model to investigate the impact of lipid dose on exogenous and endogenous lipid recruitment, and drug transport, into the lymph of males versus females. Finally, lymphatic transport and drug absorption in the mouse were compared to other pre-clinical models (rats/dogs).

A mouse model to evaluate the impact of species, sex, and lipid load on lymphatic drug transport.

This work investigates the influence of drug absorption route (intestinal lymphatics vs. blood supply) on drug pharmacokinetics and tissue distribution. To achieve this aim, the pharmacokinetics and tissue distribution of model compounds [1,1-bis(4-chlorophenyl)-2,2,2-trichloroethane, DDT; halofantrine] and lipids were assessed following intravenous delivery in lymph lipoproteins or plasma, and were found to differ significantly. For DDT, the clearance (CL) and volume of distribution (Vd ) were higher, whereas for halofantrine, CL and V(d) were lower, after entry in lymph versus plasma due, in particular, to differences in adipose tissue and liver uptake. In a recent study, halofantrine CL and V(d) were similar following entry in lymph or entry in plasma into the systemic circulation of animals predosed with lymph, whereas in the current study, predosing lymph did not influence DDT CL and V(d). For compounds such as DDT, changes to the route of absorption may thus directly impact on pharmacokinetics and tissue distribution, whereas for halofantrine factors that influence lymphatic transport may, by altering systemic lipoprotein concentrations, indirectly impact pharmacokinetics and tissue distribution. Ultimately, careful control of dosing conditions (formulation, prandial state), and thus the extent of lymphatic transport, may be important in assuring reproducible efficacy and toxicity for lymphatically transported drugs.

The impact of lymphatic transport on the systemic disposition of lipophilic drugs.

To assess the role of intestinal lymphatic transport in the oral bioavailability and brain deposition of a highly lipophilic, centrally acting drug candidate (Org 49209) in comparison to cholesterol, a close structural analogue.

The influence of intestinal lymphatic transport on the systemic exposure and brain deposition of a novel highly lipophilic compound with structural similarity to cholesterol.

Cannulation of the thoracic lymph duct in experimental animals allows direct measurement of the lymphatic exposure of lymph-targeted drugs. When coupled with recent advances in genetically modified and diseased mouse models, this presents further opportunities to define changes in biological processes and disease in response to drug treatment. Although cannulation of the thoracic lymph duct in mice is inherently challenging because of the small size and delicate nature of the duct, it can be further confounded by anatomical variations between animals. In this communication, we present our observations on the anatomical features of the thoracic lymph duct between mice of different strains and genders, and discuss the impact of these features on the "cannulatability" of the duct. We also provide some technical tips to help guide other investigators to deliver higher experimental success rates. © 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:1207-1209, 2015.

Practical lessons in murine thoracic lymph duct cannulations: observations in female and male mice across four different strains that impact on "cannulatability".

Suzanne M. Caliph

Drug Delivery,
Disposition,
and Dynamics,
Monash Institute of Pharmaceutical Sciences,
Drug Delivery, Disposition, and Dynamics, Monash Institute of Pharmaceutical Sciences

Monash University (Parkville Campus)

The Mesenteric Lymph Duct Cannulated Rat Model: Application to the Assessment of Intestinal Lymphatic Drug Transport

Suzanne M. Caliph

.css-o250i3{font-size:18px;font-family:Open Sans,sans-serif;line-height:21.6px;}Drug Delivery,Disposition,and Dynamics,Monash Institute of Pharmaceutical Sciences,Drug Delivery, Disposition, and Dynamics, Monash Institute of Pharmaceutical Sciences

Monash University (Parkville Campus)

The Mesenteric Lymph Duct Cannulated Rat Model: Application to the Assessment of Intestinal Lymphatic Drug Transport

Drug Delivery,
Disposition,
and Dynamics,
Monash Institute of Pharmaceutical Sciences,
Drug Delivery, Disposition, and Dynamics, Monash Institute of Pharmaceutical Sciences